23:14:22 EDT Tue 26 May 2026
Enter Symbol
or Name
USA
CA



Redwood AI Corp. - Common Shares
Symbol AIRX
Shares Issued 35,919,553
Close 2026-05-26 C$ 7.12
Market Cap C$ 255,747,217
Recent Sedar+ Documents

ORIGINAL: Redwood AI Announces Approval of Electronic Clearing and Settlement in the US through DTC

2026-05-26 20:00 ET - News Release

(via TheNewswire)

Redwood AI Corp.

   

 

Also Announces Marketing Announcement

Vancouver, Canada – May 26, 2026 - TheNewswire – Redwood AI Corp. (CSE: AIRX ) (OTCQB: RDWCF ) (Frankfurt: Y0N , WKN: A422EZ ) (" Redwood " or the " Company ") is pleased to announce that its common shares have been approved for electronic clearing and settlement in the United States through the Depository Trust Company (" DTC "). DTC eligibility is expected to simplify the process of trading and enhance liquidity of Redwood's shares in the United States.

DTC is a subsidiary of the Depository Trust & Clearing Corporation (“ DTCC ”) and provides electronic clearing and settlement services for publicly traded securities in the United States. DTC eligibility allows Redwood’s common shares to be held and transferred electronically through DTC’s system, which is commonly used by U.S. broker-dealers, banks and other market participants to process securities transactions.

 

“ Receiving DTC eligibility is an important step in improving access to Redwood AI for investors in the United States. By enabling electronic clearing and settlement, we believe Redwood’s shares will be more efficient for U.S. investors and brokerage firms to trade, supporting greater market efficiency and potential for broader investor participation, ” said Louis Dron, CEO of Redwood AI.

 

The Company also announces that it has engaged InvestorBrandNetwork (“ IBN ”) (business address: 1108 Lavaca Street, Suite 110-IBN, Austin, TX 78701; telephone: 512-354-7000; website: www.IBN.ai; contact email: Dutch@IBN.fm), an arm’s length third-party, to provide market awareness, corporate communications and digital media services, including editorial content, press release recap-style coverage, newsletter coverage, social media relations support, podcast-related distribution and syndication through IBN’s investor-focused media network (the “ Services ”). The Company will pay IBN an aggregate cash fee of US$114,000 for the Services. The Services are scheduled to run until September 30, 2026, or budget exhaustion, and is structured to allow for ongoing evaluation and, accordingly, may be shortened or extended at the discretion of the Company. No securities have been provided to IBN or its principals as compensation for the Services.

 

About Redwood AI Corp.

 

Redwood AI uses advanced artificial intelligence to accelerate chemistry R&D, with the aim of assisting in drug discovery and development, and furthering defense and safety solutions. The Company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. Redwood AI’s platform is designed to enable faster, more efficient development of new therapies and chemistry-driven applications.

  

ON BEHALF OF REDWOOD AI CORP.,

 

“ Louis Dron ”

Chief Executive Officer

 

For more information, please contact:

 

Louis Dron

Chief Executive Officer

 

Tel: +1 888 530 8488

investors@redwoodai.com

The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

 

Forward-Looking Statements Caution .  This news release contains statements and information that, to the extent they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information is generally identified by words such as “believe”, “expect”, “anticipate”, “estimate”, “intend”, “plan”, “may”, “should”, “will”, “potential” and similar expressions and, in this news release, includes statements relating to the anticipated benefits of DTC eligibility and the Services, the development and potential deployment of the AI-powered Platform, and the expectation that the Platform may be utilized for drug discovery or development or to further defense or safety solutions. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on it, as actual results may differ materially from those expressed or implied. Forward-looking information inherently involves risks and uncertainties, many of which are beyond the Company’s control. The forward-looking information contained in this news release is made as of the date hereof, and the Company undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise, except as required by applicable laws.

 

Copyright (c) 2026 TheNewswire - All rights reserved.

© 2026 Canjex Publishing Ltd. All rights reserved.